In the last decades, a number of infectious viruses have emerged from wildlife or re-
emerged, generating serious threats to the global health and to the economy worldwide …

Summary Since the first World Health Organization notification on 31 December 2019,
coronavirus disease 2019 (COVID‐19), the respiratory disease caused by the coronavirus …

Background Ebola vaccine development was accelerated in response to the 2014 Ebola
virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety …

Abstract Background During the 2014 West African Ebola outbreak, Ebola vaccine
development was accelerated. The phase 1 VAC52150EBL1003 study was performed to …

Background Nonlive vaccine approaches that are simple to deliver and stable at room
temperature or 2–8° C could be advantageous in controlling future Ebola virus (EBOV) …

Ebola virus (EBOV), a member of the family Filoviridae, is responsible for causing Ebola
virus disease (EVD)(formerly named Ebola hemorrhagic fever). This is a severe, often fatal …

Abstract The 2013–2016 West African Ebola outbreak was both a catastrophic public health
disaster and a rare research opportunity. This paper analyses how the tensions between the …

To evaluate the risk–benefits balance of the rVSV-ΔG-ZEBOV-GP vaccine. We performed a
systematic review to summarize data on safety, immunogenicity and efficacy. About 17,600 …

Serological assays detecting neutralising antibodies are important for determining the
immune responses following infection or vaccination and are also often considered a …

Safety and immunogenicity of two-dose regimens of Ad26. ZEBOV and MVA-BN-Filo
vaccines were evaluated in this phase 1 US study (healthy adults). Regimens were well …